Navigation Links
Boston Scientific Announces Favorable Court Ruling Dismissing Securities Fraud Case
Date:8/8/2011

NATICK, Mass., Aug. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the recall of the Company's TAXUS® Express2 Paclitaxel-Eluting Coronary Stent System in 2004.  The case, which had been filed by the Mississippi Public Employees' Retirement System, had previously been dismissed by the U.S. District Court for the District of Massachusetts.

"We are pleased with the Court's decision," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.  "The Company has made significant progress in reducing its legal exposure in the last 24 months and will continue to vigorously defend itself against allegations of this type."

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding litigation outcome, our product
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Announces $1.0B Share Repurchase Program
2. Boston Scientific Second Quarter Results Exceed Consensus Sales and EPS; Full-Year Guidance Raised
3. Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion
4. Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results
5. Boston Scientific Completes Clinical Trial Enrollment for Adapt™ Monorail™ Carotid Stent System
6. Boston Scientific Announces U.S. and European Launch of Interlock™ - 35 Fibered IDC™ Occlusion System
7. Boston Scientific Welcomes Passage of Patent Reform Bill
8. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
9. Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter
10. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
11. Boston Scientific Announces Voluntary Recall of iCross™ Coronary Imaging Catheters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  ResMed Inc. (NYSE: RMD ) today announced results ... quarter was $423.0 million, a 10 percent increase compared to ... on a constant currency basis). Net income was $91.2 million, ... December 31, 2013. Diluted earnings per share for the quarter ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ... Market by Allergen Source, Product & by End User - ... The global allergy diagnostics market is valued at ... a CAGR of 12.67%, to reach $2,230.72 million by 2019. ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Blood transfusions are a,valuable treatment mechanism in modern ... disease transmission. Researchers are continually studying the,biology of ... in an effort to reduce this risk during ... online in Blood, the official,journal of the American ...
... August 28 , - Results Further Support ... Development to Improve the Survival of Patients,With Hormone ... ALGETA), the Norwegian cancer therapeutics company,today announced that ... pain,palliation study was met. The study showed that ...
Cached Medicine Technology:Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study 2Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... the company that will become public from the planned ... today filed a second amendment to its Form 10 ... that includes information about its post-spin board of directors ... under a consent decree for its Alaris(R) infusion products. ...
... to Lowering Healthcare Costs and Expanding Viability and Adoption of ... Health professionals and patients alike have access ... stabilizing mounting healthcare costs by increasing compliance. MedApps, Inc. ... Food and Drug Administration for its expanded, flexible telehealth solution. ...
... a wide range of communication tools, including email, IM and ... coach as often as they want over a 12-month period ... than condition-focused approach to healthcare, with outreach driven by individual ... June 9 Alere LLC, a leader in ...
... in improving caregiver workflow in healthcare environments, today announced the ... its board of directors. , , "We are pleased ... help broaden the business and operating base as we meet ... "Both Bill and Carol will bring strong leadership skills, extensive ...
... alkaline pH - key to Focus, Performance, Recovery in ... June 9 AquaHydrate, the first high-performance ... through support of events and initiatives, including the famous ... to provide cellular hydration in the most demanding environments, ...
... in Phase 1a single ascending dose trial , ... dose trials are expected in second half 2009 , ... VRUS ) announced today that it had completed the ... ascending dose trial with PSI-7851, a nucleotide analog polymerase inhibitor ...
Cached Medicine News:Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 2Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 3Health News:CareFusion Announces Board of Directors, Progress on Alaris Consent Decree 4Health News:MedApps Receives FDA Clearance on a New Way to Bring Cost-Effective Remote Health Monitoring to More People 2Health News:Alere Introduces Industry's First 12-month Unlimited Health Coaching Program 2Health News:Alere Introduces Industry's First 12-month Unlimited Health Coaching Program 3Health News:ThinIdentity(TM) Announces Two New Board Members 2Health News:ThinIdentity(TM) Announces Two New Board Members 3Health News:The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including 'Mud Run' 2Health News:The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including 'Mud Run' 3Health News:The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including 'Mud Run' 4Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 2Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 3Health News:Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients 4
Standard Lipo-tubing...
... Screening, Supplemental Confirmatory (Western Blot): The assay ... antigens on their surface. The cells are ... glass slide. Fixed, uninfected T-cells are provided ... plasma sample with HIV- I antibodies comes ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
Inquire...
Medicine Products: